The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
Recruiting · NCT06601010 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ruijin Hospital
View the official record on ClinicalTrials.gov →What this trial is about
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines
- Signed and dated informed consent form
- Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of \> 6 months
Exclusion criteria
- Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- Intestinal perforation, complete intestinal obstruction
- Pregnant women and women who may be pregnant, women who are breastfeeding.
- Non-compliant person
Where it is running
1 location listed.
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine - Shanghai, Shanghai Municipality, China